Colorectal cancer (CRC) screening has become more complex, and more controversial, following the 2022 NordICC trial — the first large randomized trial to test colonoscopy versus no colonoscopy for CRC prevention in the general population, with results that surprised many gastroenterologists and prompted significant debate about how to interpret existing evidence.
The NordICC Trial and Its Interpretation
NordICC (2022, NEJM, n=84,585): first RCT of colonoscopy screening versus no colonoscopy in 55–64-year-olds across Poland, Norway, and Sweden. Randomized 28,220 to colonoscopy invitation. Results: invitation-group (31% uptake) showed 18% reduction in CRC risk and 10% reduction in CRC-related death (not statistically significant). Per-protocol analysis (those who actually underwent colonoscopy): 31% CRC risk reduction and 50% CRC-death reduction — suggesting substantial benefit in those who complied. Critical interpretation issue: the 69% who declined colonoscopy invitation are analyzed in the "colonoscopy group" in intention-to-treat analysis, dramatically diluting the apparent benefit. The per-protocol numbers are more clinically meaningful for actual colonoscopy effects. NordICC context: European colonoscopy quality metrics differ from US (US has higher adenoma detection rates — ADR — associated with better cancer prevention). The findings should not be extrapolated to dismiss colonoscopy in high-ADR US programs.
Comparative Screening Options
Annual FIT (fecal immunochemical test): sensitivity for CRC 79%, specificity 94% — extremely low cost ($15–25), no bowel prep, no sedation. Annual requirement is a limitation. Cologuard (stool DNA + FIT combined, Exact Sciences): CRC sensitivity 92.3%, advanced adenoma sensitivity 42.4%, specificity 86.6% — approved every 3 years. Higher sensitivity than FIT alone for CRC; substantially lower specificity. Positive test requires follow-up colonoscopy. Colonoscopy (every 10 years): "gold standard" for both screening and polypectomy — can detect and remove adenomas in the same procedure. Perforation risk 1/1,000, bleeding risk 1/300 for polypectomy. Current USPSTF guidance (2021): Grade A recommendation to screen all adults ages 45–75; choice of modality is explicitly a shared decision between patient and provider based on patient preferences — no single screening method is universally mandated. For clinical gastroenterology practices and hospital systems, our medical gloves, wound care supplies, and PPE catalog include procedural supplies supporting CRC screening programs.
